CLINICAL_TRIALS
trial_result
· 2012-05-18
Clinical Trial Update: The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP) [Phase 3]
Summary
A Phase 3 trial evaluating Unasyn-S 12 g/day for community-acquired pneumonia has completed and results were posted in 2012.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Pneumonia, Bacterial | Phase 3 | Status: COMPLETED | Results posted: 2012-05-18